RO.CH

257.2

-0.39%↓

NOVN.CH

96.45

-0.11%↓

LONN.CH

540

-0.04%↓

RO.CH

257.2

-0.39%↓

NOVN.CH

96.45

-0.11%↓

LONN.CH

540

-0.04%↓

RO.CH

257.2

-0.39%↓

NOVN.CH

96.45

-0.11%↓

LONN.CH

540

-0.04%↓

RO.CH

257.2

-0.39%↓

NOVN.CH

96.45

-0.11%↓

LONN.CH

540

-0.04%↓

RO.CH

257.2

-0.39%↓

NOVN.CH

96.45

-0.11%↓

LONN.CH

540

-0.04%↓

Search

Bachem Holding AG

Open

SectorHealthcare

67.3 0.75

Overview

Share price change

24h

Current

Min

66.4

Max

67.6

Key metrics

By Trading Economics

Income

-34M

50M

Sales

-52M

313M

P/E

Sector Avg

39.157

34.393

EPS

0.67

Dividend yield

1.27

Profit margin

16.007

Employees

2,292

EBITDA

118M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+18.57% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

1.27%

2.54%

Market Stats

By TradingEconomics

Market Cap

-349M

5B

Previous open

66.55

Previous close

67.3

News Sentiment

By Acuity

50%

50%

162 / 374 Ranking in Healthcare

Bachem Holding AG Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

6 gru 2024, 11:00 UTC

Market Talk

Bachem Has Challenging Years Ahead With Strong Capital Expenditure -- Market Talk

Peer Comparison

Price change

Bachem Holding AG Forecast

Price Target

By TipRanks

18.57% upside

12 Months Forecast

Average 79.5 CHF  18.57%

High 86 CHF

Low 75 CHF

Based on 6 Wall Street analysts offering 12 month price targets forBachem Holding AG - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

4

Buy

2

Hold

0

Sell

Sentiment

By Acuity

162 / 374 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Bachem Holding AG

Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. Bachem Holding AG was founded in 1971 and is headquartered in Bubendorf, Switzerland.